Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Aug;59(2):165–169. doi: 10.1136/jnnp.59.2.165

Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies.

D S Molenaar 1, R de Haan 1, M Vermeulen 1
PMCID: PMC485992  PMID: 7629531

Abstract

Outcome measures can be classified into measures of impairment, disability, and handicap. To investigate the biological effect of treatment, measures of impairment are appropriate. Studies investigating whether patients benefit from treatment in terms of improvement of functional health, however, require disability or handicap measures. In a review of the medical literature between 1978 and 1993, 73 controlled intervention studies in patients with peripheral neuropathies were found. Disability or handicap measures were used in two of 54 studies in patients with diabetic neuropathy, in two of six studies in patients with chronic inflammatory demyelinating polyneuropathy, in none of five studies in a mixed group of patients, and in all eight studies in patients with Guillain-Barré syndrome. The limited use of disability and handicap measures in patients with diabetic and mixed neuropathies can be explained by the experimental nature of most studies. In four of six studies, however, in patients with chronic inflammatory demyelinating polyneuropathy or neuropathy associated with monoclonal gammopathy that were designed to assess effectiveness of treatment, the choice of outcome measures was not appropriate. It is concluded that in the design of intervention studies in patients with peripheral neuropathy more attention should be paid to a proper choice of suitable outcome measures to assess the effectiveness of treatment.

Full text

PDF
165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham R. R., Abraham R. M., Wynn V. A double blind placebo controlled trial of mixed gangliosides in diabetic peripheral and autonomic neuropathy. Adv Exp Med Biol. 1984;174:607–624. doi: 10.1007/978-1-4684-1200-0_52. [DOI] [PubMed] [Google Scholar]
  2. Boulton A. J., Levin S., Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 1990 Jul;33(7):431–437. doi: 10.1007/BF00404095. [DOI] [PubMed] [Google Scholar]
  3. Cohen K. L., Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med. 1987 Aug;147(8):1442–1444. [PubMed] [Google Scholar]
  4. Crepaldi G., Fedele D., Tiengo A., Battistin L., Negrin P., Pozza G., Canal N., Comi G. C., Lenti G., Pagano G. Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. Acta Diabetol Lat. 1983 Jul-Sep;20(3):265–276. doi: 10.1007/BF02581271. [DOI] [PubMed] [Google Scholar]
  5. De Leeuw I. H., Van Rooy P., Moeremans M., Driessens M. Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy. Drugs. 1987;33 (Suppl 2):125–130. doi: 10.2165/00003495-198700332-00023. [DOI] [PubMed] [Google Scholar]
  6. Dejgard A., Petersen P., Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet. 1988 Jan 2;1(8575-6):9–11. doi: 10.1016/s0140-6736(88)90999-3. [DOI] [PubMed] [Google Scholar]
  7. Djoenaidi W., Notermans S. L. Thiamine tetraphydrofurfuryl disulfide in nutritional polyneuropathy. Eur Arch Psychiatry Neurol Sci. 1990;239(4):218–220. doi: 10.1007/BF01738575. [DOI] [PubMed] [Google Scholar]
  8. Dukanović L., Petrović J., Potić J. Middle molecular weight substances and uremic polyneuropathy. Acta Med Iugosl. 1990;44(2):117–128. [PubMed] [Google Scholar]
  9. Dyck P. J., Daube J., O'Brien P., Pineda A., Low P. A., Windebank A. J., Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986 Feb 20;314(8):461–465. doi: 10.1056/NEJM198602203140801. [DOI] [PubMed] [Google Scholar]
  10. Dyck P. J., Low P. A., Windebank A. J., Jaradeh S. S., Gosselin S., Bourque P., Smith B. E., Kratz K. M., Karnes J. L., Evans B. A. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991 Nov 21;325(21):1482–1486. doi: 10.1056/NEJM199111213252105. [DOI] [PubMed] [Google Scholar]
  11. Dyck P. J., O'Brien P. C., Oviatt K. F., Dinapoli R. P., Daube J. R., Bartleson J. D., Mokri B., Swift T., Low P. A., Windebank A. J. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982 Feb;11(2):136–141. doi: 10.1002/ana.410110205. [DOI] [PubMed] [Google Scholar]
  12. Dyck P. J., O'Brien P., Swanson C., Low P., Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985 Aug;35(8):1173–1176. doi: 10.1212/wnl.35.8.1173. [DOI] [PubMed] [Google Scholar]
  13. Fagius J., Brattberg A., Jameson S., Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia. 1985 Jun;28(6):323–329. doi: 10.1007/BF00283137. [DOI] [PubMed] [Google Scholar]
  14. Fagius J., Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):991–1001. doi: 10.1136/jnnp.44.11.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Florkowski C. M., Rowe B. R., Nightingale S., Harvey T. C., Barnett A. H. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes. 1991 Jan;40(1):129–133. doi: 10.2337/diab.40.1.129. [DOI] [PubMed] [Google Scholar]
  16. Gill J. S., Williams G., Ghatei M. A., Hetreed A. H., Mather H. M., Bloom S. R. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabete Metab. 1990 Jul-Aug;16(4):296–302. [PubMed] [Google Scholar]
  17. Gomez-Perez F. J., Rull J. A., Dies H., Rodriquez-Rivera J. G., Gonzalez-Barranco J., Lozano-Castañeda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain. 1985 Dec;23(4):395–400. doi: 10.1016/0304-3959(85)90010-7. [DOI] [PubMed] [Google Scholar]
  18. Greenwood R. J., Newsom-Davis J., Hughes R. A., Aslan S., Bowden A. N., Chadwick D. W., Gordon N. S., McLellan D. L., Millac P., Stott R. B. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984 Apr 21;1(8382):877–879. doi: 10.1016/s0140-6736(84)91341-2. [DOI] [PubMed] [Google Scholar]
  19. Hotta N., Kawamori R., Sano T., Kakuta H., Kamada T., Sakamoto N. Diabetic neuropathy: effects of intensified glycaemic control with multiple insulin injections. Diabet Med. 1993;10 (Suppl 2):91S–94S. doi: 10.1111/j.1464-5491.1993.tb00211.x. [DOI] [PubMed] [Google Scholar]
  20. Hughes R. A., Newsom-Davis J. M., Perkin G. D., Pierce J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978 Oct 7;2(8093):750–753. doi: 10.1016/s0140-6736(78)92644-2. [DOI] [PubMed] [Google Scholar]
  21. Jamal G. A., Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med. 1990 May;7(4):319–323. doi: 10.1111/j.1464-5491.1990.tb01397.x. [DOI] [PubMed] [Google Scholar]
  22. Jaspan J., Maselli R., Herold K., Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet. 1983 Oct 1;2(8353):758–762. doi: 10.1016/s0140-6736(83)92296-1. [DOI] [PubMed] [Google Scholar]
  23. Jennett B., Bond M. Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480–484. doi: 10.1016/s0140-6736(75)92830-5. [DOI] [PubMed] [Google Scholar]
  24. Kastrup J., Petersen P., Dejgård A., Angelo H. R., Hilsted J. Intravenous lidocaine infusion--a new treatment of chronic painful diabetic neuropathy? Pain. 1987 Jan;28(1):69–75. doi: 10.1016/0304-3959(87)91061-X. [DOI] [PubMed] [Google Scholar]
  25. Kleyweg R. P., van der Meché F. G., Schmitz P. I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve. 1991 Nov;14(11):1103–1109. doi: 10.1002/mus.880141111. [DOI] [PubMed] [Google Scholar]
  26. Kvinesdal B., Molin J., Frøland A., Gram L. F. Imipramine treatment of painful diabetic neuropathy. JAMA. 1984 Apr 6;251(13):1727–1730. [PubMed] [Google Scholar]
  27. Lehtinen J. M., Hyvönen S. K., Uusitupa M., Puhakainen E., Halonen T., Kilpeläinen H. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy. J Neurol. 1986 Jun;233(3):174–177. doi: 10.1007/BF00314428. [DOI] [PubMed] [Google Scholar]
  28. Lewin I. G., O'Brien I. A., Morgan M. H., Corrall R. J. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia. 1984 Jun;26(6):445–448. doi: 10.1007/BF00262218. [DOI] [PubMed] [Google Scholar]
  29. Liniger C., Pernet A., Moody J. F., Assal J. P. Effect of gangliosides on diabetic peripheral neuropathy. Diabetes Res Clin Pract. 1989 Nov 6;7(4):251–258. doi: 10.1016/0168-8227(89)90012-0. [DOI] [PubMed] [Google Scholar]
  30. Mamoli B., Brunner G., Mader R., Schanda H. Effects of cerebral gangliosides in the alcoholic polyneuropathies. Eur Neurol. 1980;19(5):320–326. doi: 10.1159/000115168. [DOI] [PubMed] [Google Scholar]
  31. Markus H. S., Brown M. M. Differentiation between different pathological cerebral embolic materials using transcranial Doppler in an in vitro model. Stroke. 1993 Jan;24(1):1–5. doi: 10.1161/01.str.24.1.1. [DOI] [PubMed] [Google Scholar]
  32. Martyn C. N., Reid W., Young R. J., Ewing D. J., Clarke B. F. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Diabetes. 1987 Sep;36(9):987–990. doi: 10.2337/diab.36.9.987. [DOI] [PubMed] [Google Scholar]
  33. Max M. B., Culnane M., Schafer S. C., Gracely R. H., Walther D. J., Smoller B., Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987 Apr;37(4):589–596. doi: 10.1212/wnl.37.4.589. [DOI] [PubMed] [Google Scholar]
  34. Max M. B., Lynch S. A., Muir J., Shoaf S. E., Smoller B., Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992 May 7;326(19):1250–1256. doi: 10.1056/NEJM199205073261904. [DOI] [PubMed] [Google Scholar]
  35. Mendel C. M., Klein R. F., Chappell D. A., Dere W. H., Gertz B. J., Karam J. H., Lavin T. N., Grunfeld C. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA. 1986 Feb 7;255(5):637–639. [PubMed] [Google Scholar]
  36. Mendell J. R., Kissel J. T., Kennedy M. S., Sahenk Z., Grinvalsky H. T., Pittman G. L., Kyler R. S., Roelofs R. I., Whitaker J. N., Bertorini T. E. Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology. 1985 Nov;35(11):1551–1555. doi: 10.1212/wnl.35.11.1551. [DOI] [PubMed] [Google Scholar]
  37. Naarden A., Davidson J., Harris L., Moore J., DeFelice S. Treatment of painful diabetic polyneuropathy with mixed gangliosides. Adv Exp Med Biol. 1984;174:581–592. doi: 10.1007/978-1-4684-1200-0_49. [DOI] [PubMed] [Google Scholar]
  38. O'Hare J. P., Morgan M. H., Alden P., Chissel S., O'Brien I. A., Corrall R. J. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabet Med. 1988 Sep;5(6):537–542. doi: 10.1111/j.1464-5491.1988.tb01047.x. [DOI] [PubMed] [Google Scholar]
  39. Osterman P. O., Fagius J., Lundemo G., Pihlstedt P., Pirskanen R., Sidén A., Säfwenberg J. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984 Dec 8;2(8415):1296–1299. doi: 10.1016/s0140-6736(84)90819-5. [DOI] [PubMed] [Google Scholar]
  41. RANKIN J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957 May;2(5):200–215. doi: 10.1177/003693305700200504. [DOI] [PubMed] [Google Scholar]
  42. Sachse G., Willms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Horm Metab Res Suppl. 1980;9:105–107. [PubMed] [Google Scholar]
  43. Salway J. G., Whitehead L., Finnegan J. A., Karunanayaka A., Barnett D., Payne R. B. Effect of myo-inositol on peripheral-nerve function in diabetes. Lancet. 1978 Dec 16;2(8103):1282–1284. doi: 10.1016/s0140-6736(78)92043-3. [DOI] [PubMed] [Google Scholar]
  44. Santiago J. V., Snksen P. H., Boulton A. J., Macleod A., Beg M., Bochenek W., Graepel G. J., Gonen B. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications. 1993 Jul-Sep;7(3):170–178. doi: 10.1016/1056-8727(93)90042-w. [DOI] [PubMed] [Google Scholar]
  45. Sima A. A., Bril V., Nathaniel V., McEwen T. A., Brown M. B., Lattimer S. A., Greene D. A. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med. 1988 Sep 1;319(9):548–555. doi: 10.1056/NEJM198809013190905. [DOI] [PubMed] [Google Scholar]
  46. Sindrup S. H., Bjerre U., Dejgaard A., Brøsen K., Aaes-Jørgensen T., Gram L. F. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547–552. doi: 10.1038/clpt.1992.183. [DOI] [PubMed] [Google Scholar]
  47. Sindrup S. H., Ejlertsen B., Frøland A., Sindrup E. H., Brøsen K., Gram L. F. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol. 1989;37(2):151–153. doi: 10.1007/BF00558223. [DOI] [PubMed] [Google Scholar]
  48. Sindrup S. H., Gram L. F., Brøsen K., Eshøj O., Mogensen E. F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990 Aug;42(2):135–144. doi: 10.1016/0304-3959(90)91157-E. [DOI] [PubMed] [Google Scholar]
  49. Sindrup S. H., Gram L. F., Skjold T., Grodum E., Brøsen K., Beck-Nielsen H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol. 1990 Nov;30(5):683–691. doi: 10.1111/j.1365-2125.1990.tb03836.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Sindrup S. H., Tuxen C., Gram L. F., Grodum E., Skjold T., Brøsen K., Beck-Nielsen H. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol. 1992;43(3):251–255. doi: 10.1007/BF02333018. [DOI] [PubMed] [Google Scholar]
  51. Stracke H., Meyer U. E., Schumacher H. E., Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care. 1992 Nov;15(11):1550–1555. doi: 10.2337/diacare.15.11.1550. [DOI] [PubMed] [Google Scholar]
  52. Sundkvist G., Armstrong F. M., Bradbury J. E., Chaplin C., Ellis S. H., Owens D. R., Rosén I., Sönksen P. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications. 1992 Apr-Jun;6(2):123–130. doi: 10.1016/1056-8727(92)90023-e. [DOI] [PubMed] [Google Scholar]
  53. Toyota T., Hirata Y., Ikeda Y., Matsuoka K., Sakuma A., Mizushima Y. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins. 1993 Nov;46(5):453–468. doi: 10.1016/0090-6980(93)90081-h. [DOI] [PubMed] [Google Scholar]
  54. Vermeulen M., van Doorn P. A., Brand A., Strengers P. F., Jennekens F. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36–39. doi: 10.1136/jnnp.56.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Visser M. C., Koudstaal P. J., van Latum J. C., Frericks H., Berengholz-Zlochin S. N., van Gijn J. Variatie tussen waarnemers bij de toepassing van twee invaliditeitsschalen bij hartpatiënten. Ned Tijdschr Geneeskd. 1992 Apr 25;136(17):831–834. [PubMed] [Google Scholar]
  56. Yaqub B. A., Siddique A., Sulimani R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg. 1992;94(2):105–111. doi: 10.1016/0303-8467(92)90066-c. [DOI] [PubMed] [Google Scholar]
  57. Young R. J., Clarke B. F. Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs. Diabet Med. 1985 Sep;2(5):363–366. doi: 10.1111/j.1464-5491.1985.tb00652.x. [DOI] [PubMed] [Google Scholar]
  58. Young R. J., Ewing D. J., Clarke B. F. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes. 1983 Oct;32(10):938–942. doi: 10.2337/diab.32.10.938. [DOI] [PubMed] [Google Scholar]
  59. Zeigler D., Lynch S. A., Muir J., Benjamin J., Max M. B. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain. 1992 Mar;48(3):403–408. doi: 10.1016/0304-3959(92)90092-P. [DOI] [PubMed] [Google Scholar]
  60. Ziegler D., Mayer P., Rathmann W., Gries F. A. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract. 1991 Oct;14(1):63–73. doi: 10.1016/0168-8227(91)90054-h. [DOI] [PubMed] [Google Scholar]
  61. de Haan R., Aaronson N., Limburg M., Hewer R. L., van Crevel H. Measuring quality of life in stroke. Stroke. 1993 Feb;24(2):320–327. doi: 10.1161/01.str.24.2.320. [DOI] [PubMed] [Google Scholar]
  62. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]
  63. van Gerven J. M., Lemkes H. H., van Dijk J. G. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. J Diabetes Complications. 1992 Jan-Mar;6(1):45–48. doi: 10.1016/1056-8727(92)90048-p. [DOI] [PubMed] [Google Scholar]
  64. van Swieten J. C., Koudstaal P. J., Visser M. C., Schouten H. J., van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604–607. doi: 10.1161/01.str.19.5.604. [DOI] [PubMed] [Google Scholar]
  65. van der Hoop R. G., Vecht C. J., van der Burg M. E., Elderson A., Boogerd W., Heimans J. J., Vries E. P., van Houwelingen J. C., Jennekens F. G., Gispen W. H. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990 Jan 11;322(2):89–94. doi: 10.1056/NEJM199001113220204. [DOI] [PubMed] [Google Scholar]
  66. van der Meché F. G., Schmitz P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992 Apr 23;326(17):1123–1129. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES